Osteoporosis - Intermittent dosing drives market growth

The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries.

Despite the genericization of the market leader Fosamax in the US and Japan and patent expiries on other key brands, pipeline products are still viable. Datamonitor expects pipeline products to swell the total market value 59.6% between 2007 and 2016 to $11.1 billion.

Products that offer intermittent dosing schedules are highly desirable in the osteoporosis market and can generate blockbuster revenues. Such therapies answer the demand from patients and physicians for more convenient delivery mechanisms that increase compliance and ultimately improve treatment outcome.

Although bisphosphonates are the mainstay of osteoporosis treatment, there is potential for new and innovative products to gain market share. Those that suit niche populations, such as Amgen's ED-71 which finds favor as a vitamin D analogue in Japan, will be able to fight generic competition.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Medicare Part D (21/05/2008)
• Influenza Vaccines (21/05/2008)
• Antithrombotics (21/05/2008)
• Dyslipidemia (21/05/2008)
• Insomnia (21/05/2008)
• Fibromyalgia (21/05/2008)
• Canadian Generics Market (21/05/2008)
• Female Sexual Dysfunction (21/05/2008)
• Supportive Care in Oncology (21/05/2008)

---